Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Study Overview: Amgen Inc. is conducting a Phase 3 study titled Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301). The study aims to compare progression-free survival in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving a combination of sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb.
Intervention/Treatment: The study tests two main interventions. Arm A includes sotorasib, panitumumab, and FOLFIRI, while Arm B involves FOLFIRI with or without bevacizumab-awwb. Sotorasib is an oral tablet, while panitumumab and FOLFIRI are administered intravenously every two weeks.
Study Design: This interventional study is randomized with a parallel assignment model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused.
Study Timeline: The study began on July 17, 2024, with the latest update submitted on June 25, 2025. These dates are crucial as they indicate the study’s progression and the timeline for potential results.
Market Implications: This study could significantly impact Amgen’s stock performance and investor sentiment, especially if the results demonstrate a clear benefit over existing treatments. The competitive landscape in metastatic colorectal cancer treatments may shift, influencing market dynamics and potentially affecting competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.